Editorial
Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?
Translational Cancer Research
2019;
8
(Suppl 2)
:S79-S83
.
(28 March 2019)
Postmastectomy radiation therapy in women with T1–T2 tumors and 1 to 3 positive lymph nodes: analysis of the breast international group 02-98 trial
Translational Cancer Research
2019;
8
(Suppl 2)
:S84-S86
.
(28 March 2019)
Anti-GD2 CAR T cells could prove transformative for H3-K27M+ diffuse midline gliomas
Translational Cancer Research
2019;
8
(Suppl 2)
:S87-S93
.
(28 March 2019)
The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
Translational Cancer Research
2019;
8
(Suppl 2)
:S94-S96
.
(28 March 2019)
Value of magnetic resonance imaging in predicting BRAF mutation in craniopharyngiomas
Translational Cancer Research
2019;
8
(Suppl 2)
:S97-S98
.
(28 March 2019)
A new paradox for pCR in BRCA mutation carriers
Translational Cancer Research
2019;
8
(Suppl 2)
:S99-S102
.
(28 March 2019)
Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
Translational Cancer Research
2019;
8
(Suppl 2)
:S103-S105
.
(28 March 2019)
CircNT5E/miR-422a: a new circRNA-based ceRNA network in glioblastoma
Translational Cancer Research
2019;
8
(Suppl 2)
:S106-S109
.
(28 March 2019)
Whether adjuvant radiotherapy is desired for postmastectomy patients with T1–T2 tumors and 1–3 positive axillary lymph nodes who received modern systemic therapy?
Translational Cancer Research
2019;
8
(Suppl 2)
:S110-S114
.
(28 March 2019)
Proton beam radiosurgery: early clinical results
Translational Cancer Research
2019;
8
(Suppl 2)
:S115-S117
.
(28 March 2019)
Impact of breast surgery in de novo stage IV breast cancer
Translational Cancer Research
2019;
8
(Suppl 2)
:S118-S119
.
(28 March 2019)
Evolving development of multi-parametric normal tissue complication probability model for liver radiotherapy
Translational Cancer Research
2019;
8
(Suppl 2)
:S120-S123
.
(28 March 2019)
Development and validation of a polygenic hazard score for aggressive prostate cancer identification
Translational Cancer Research
2019;
8
(Suppl 2)
:S124-S125
.
(28 March 2019)
Circular RNA as a prospective molecular tool for the study of neuroprotection in cerebral ischemia
Translational Cancer Research
2019;
8
(Suppl 2)
:S126-S129
.
(28 March 2019)
The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape
Translational Cancer Research
2019;
8
(Suppl 2)
:S130-S132
.
(28 March 2019)
ARID1A: guardian of normal pancreatic ducts
Translational Cancer Research
2019;
8
(Suppl 2)
:S133-S134
.
(28 March 2019)
Twist1 activated circRNA-10720 is a new player in hepatocellular carcinoma metastasis
Translational Cancer Research
2019;
8
(Suppl 2)
:S135-S140
.
(28 March 2019)
Prospects for cost-effective lung cancer screening using risk calculators
Translational Cancer Research
2019;
8
(Suppl 2)
:S141-S144
.
(28 March 2019)
Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
Translational Cancer Research
2019;
8
(Suppl 2)
:S145-S148
.
(28 March 2019)
Metastasis suppression and enhancement of anti-tumour immunity by targeting the FSTL1-DIP2A axis
Translational Cancer Research
2019;
8
(Suppl 2)
:S149-S151
.
(28 March 2019)
Editorial on the integrated multidisciplinary algorithm for the management of spinal metastases
Translational Cancer Research
2019;
8
(Suppl 2)
:S152-S155
.
(28 March 2019)
The time has come to pull renal cancer’s sweet tooth
Translational Cancer Research
2019;
8
(Suppl 2)
:S156-S161
.
(28 March 2019)
Bevacizumab in recurrent glioblastoma
Translational Cancer Research
2019;
8
(Suppl 2)
:S162-S163
.
(28 March 2019)
The updated AJCC/TNM staging system (8th edition) for oral tongue cancer
Translational Cancer Research
2019;
8
(Suppl 2)
:S164-S166
.
(28 March 2019)
(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas
Translational Cancer Research
2019;
8
(Suppl 2)
:S167-S170
.
(28 March 2019)
Oligometastatic prostate cancer: is it worth targeting the tip of the iceberg?
Translational Cancer Research
2019;
8
(Suppl 2)
:S171-S175
.
(28 March 2019)
Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?
Translational Cancer Research
2019;
8
(Suppl 2)
:S176-S179
.
(28 March 2019)
Role of pelvic lymph node dissection in bladder cancer: is it better to do more?
Translational Cancer Research
2019;
8
(Suppl 2)
:S180-S182
.
(28 March 2019)
Squaring the circle: sponging microRNAs in gastric cancer
Translational Cancer Research
2019;
8
(Suppl 2)
:S183-S187
.
(28 March 2019)
Treatment intensity in locoregionally advanced head and neck cancer: recent investigation leads to new questions
Translational Cancer Research
2019;
8
(Suppl 2)
:S188-S194
.
(28 March 2019)
Circular RNA YAP1: a new player in gastric cancer
Translational Cancer Research
2019;
8
(Suppl 2)
:S195-S197
.
(28 March 2019)
Multimodal action of ONECUT2 in driving neuroendocrine prostate cancer
Translational Cancer Research
2019;
8
(Suppl 2)
:S198-S203
.
(28 March 2019)
Editorial Commentary
Massively parallel sequencing of urinary DNA—the dawn of non-invasive bladder cancer detection and surveillance?
Translational Cancer Research
2019;
8
(Suppl 2)
:S204-S207
.
(28 March 2019)
Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial
Translational Cancer Research
2019;
8
(Suppl 2)
:S208-S210
.
(28 March 2019)
The control of tumor progression by circular RNAs: novel prognostic and therapeutic insights resulting from the analysis of the circAGO2/human antigen R complex
Translational Cancer Research
2019;
8
(Suppl 2)
:S211-S215
.
(28 March 2019)
